Amcinafide is triamcinolone acetophenide exerting antiinflammatory and antiallergic properties.

Cyclofenil is a anti-estrogen drug developed for the treatment of female infertility and for induction of ovulation. Cyclofenil exerts its action by binding to estrogen receptor beta and demonstrates agonism or antagonism depending on tissues type. The drug was withdrawn from the market due to high risk of hepatotoxicity.

Dipyrocetyl (2,3-diacetyloxybenzoic acid) is a drug used as an analgesics and antipyretics. Besides, was shown, that it may be useful in the treatment of acute lung injury (ALI) associated with acute respiratory distress syndrome (ARDS). Dipyrocetyl possesses the anticoagulation properties, which may contribute directly to improve tissue integrity as well as indirectly by the prevention of activation of pro-inflammatory cytokines. In addition, was made a suggestion, that the drug may function as an MMP inhibitor.

Acreozast is an orally active antiallergic agent, which has anti-inflammatory activity. It was undergoing phase II clinical trials in Japan for the following condition: Asthma and Atopic dermatitis. Toyobo discontinued the development of acreozast in 1996.

Lonapalene (6-chloro-2,3-dimethoxynaphthalene-1,4-diol-diacetate; RS-43179) is a topically effective 5-lipoxygenase inhibitor. Lonapalene was shown to inhibit platelet cyclooxygenase. Lonapalene has been studied in the treatment of psoriasis. Development of lonapalene has been discontinued.

Acetomenaphthane, A vitamin K analogue used to treat and prevent hypoprothrombinemia caused by vitamin K deficiency. Also called menadiol diacetate. Hypoprothrombinemia is a blood disorder in which a deficiency of prothrombin results in impaired blood clotting, leading to an increased physiological risk for bleeding, especially in the gastrointestinal system, cranial vault, and superficial integumentary system.